Enter to search.

Parsortix blood test has the potential to out perform current standard of care in detecting ovarian cancer

UK liquid biopsy group Angle has released trial findings that indicate its Parsortix blood test has the potential to out-perform the current standard of care in detecting ovarian cancer.

The company said headline results from trials involving a total of 400 patients with a pelvic mass studies show the potential for Parsortix to discriminate between benign and malignant pelvic tumours with a degree of sensitivity, having correctly identifyied cancer in up to 95 percent of cases whilst achieving a higher specificity (low false positive rate) than existing tests

0 comments

Add a Comment

*
*

What our patients have to say about us